ClinicalTrials.gov record
Withdrawn Phase 2 Interventional

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

ClinicalTrials.gov ID: NCT03446144

Public ClinicalTrials.gov record NCT03446144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary (GA) to Age-Related Macular Degeneration (AMD)

Study identification

NCT ID
NCT03446144
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • IONIS-FB-Lrx Drug
  • Placebo (sterline saline 0.9%) Drug

Drug

Eligibility (public fields only)

Age range
55 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 15, 2018
Primary completion
Oct 9, 2018
Completion
Oct 9, 2018
Last update posted
Aug 12, 2019

2018

United States locations

U.S. sites
24
U.S. states
11
U.S. cities
23
Facility City State ZIP Site status
IONIS Investigative Site Phoenix Arizona 85014-2709
IONIS Investigational Site Beverly Hills California 90211
IONIS Investigative Site Encino California 91436
IONIS Investigative Site Irvine California 92697
IONIS Investigational Site Mountain View California 94040
IONIS Investigational Site Santa Barbara California 93103
IONIS Investigative Site Clearwater Florida 33761
IONIS Investigational Site Tampa Florida 33612
IONIS Investigational Site Augusta Georgia 30909
IONIS Investigational Site Leawood Kansas 66211
IONIS Investigative Site Chesterfield Missouri 63017
IONIS Investigative Site New York New York 10021
IONIS Investigative Site Philadelphia Pennsylvania 19104
IONIS Investigative Site Philadelphia Pennsylvania 19107-5109
IONIS Investigative Site Pittsburgh Pennsylvania 15213
IONIS Investigational Site Ladson South Carolina 29456
IONIS Investigative Site Rapid City South Dakota 57701-7374
IONIS Investigative Site Arlington Texas 76012-2505
IONIS Investigational Site Austin Texas 78705
IONIS Investigative Site Dallas Texas 75231-5078
IONIS Investigative Site Houston Texas 77030-2727
IONIS Investigative Site McAllen Texas 78503-1518
IONIS Investigative Site San Antonio Texas 78240-1502
IONIS Investigative Site The Woodlands Texas 77384-8018

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03446144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2019 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03446144 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →